Cargando…
Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
Prostacyclins are the mainstay treatment for patients with severe pulmonary arterial hypertension. This case highlights the transition from selexipag to oral treprostinil. Our patient improved both subjectively and objectively. Cardiac output and index, as measured by the echocardiogram, improved 12...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144673/ https://www.ncbi.nlm.nih.gov/pubmed/32292582 http://dx.doi.org/10.1177/2045894019898032 |
_version_ | 1783519874120679424 |
---|---|
author | Oriaku, Ifeoma Patel, Amol Safdar, Zeenat |
author_facet | Oriaku, Ifeoma Patel, Amol Safdar, Zeenat |
author_sort | Oriaku, Ifeoma |
collection | PubMed |
description | Prostacyclins are the mainstay treatment for patients with severe pulmonary arterial hypertension. This case highlights the transition from selexipag to oral treprostinil. Our patient improved both subjectively and objectively. Cardiac output and index, as measured by the echocardiogram, improved 12% and 7.7%, respectively. Invasive hemodynamic data revealed greater improvements: cardiac output improved by 25% and cardiac index by 28%. Mixed venous oxygen saturation improved from 65% to 71%. A possible explanation is that selexipag has a maximal dose, whereas there is no recommended maximum dose of oral treprostinil. Another theory is oral treprostinil has higher affinity to the IP receptor, though selexipag has a higher specificity. However, there are no bio-equivalency data, and data comparing pharmacodynamics of both drugs are lacking. Furthermore, no head-to-head trials comparing these agents exist. |
format | Online Article Text |
id | pubmed-7144673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-71446732020-04-14 Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension Oriaku, Ifeoma Patel, Amol Safdar, Zeenat Pulm Circ Case Report Prostacyclins are the mainstay treatment for patients with severe pulmonary arterial hypertension. This case highlights the transition from selexipag to oral treprostinil. Our patient improved both subjectively and objectively. Cardiac output and index, as measured by the echocardiogram, improved 12% and 7.7%, respectively. Invasive hemodynamic data revealed greater improvements: cardiac output improved by 25% and cardiac index by 28%. Mixed venous oxygen saturation improved from 65% to 71%. A possible explanation is that selexipag has a maximal dose, whereas there is no recommended maximum dose of oral treprostinil. Another theory is oral treprostinil has higher affinity to the IP receptor, though selexipag has a higher specificity. However, there are no bio-equivalency data, and data comparing pharmacodynamics of both drugs are lacking. Furthermore, no head-to-head trials comparing these agents exist. SAGE Publications 2020-04-08 /pmc/articles/PMC7144673/ /pubmed/32292582 http://dx.doi.org/10.1177/2045894019898032 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Oriaku, Ifeoma Patel, Amol Safdar, Zeenat Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension |
title | Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension |
title_full | Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension |
title_fullStr | Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension |
title_full_unstemmed | Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension |
title_short | Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension |
title_sort | transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144673/ https://www.ncbi.nlm.nih.gov/pubmed/32292582 http://dx.doi.org/10.1177/2045894019898032 |
work_keys_str_mv | AT oriakuifeoma transitionfromselexipagtooraltreprostinilinapatientwithpulmonaryarterialhypertension AT patelamol transitionfromselexipagtooraltreprostinilinapatientwithpulmonaryarterialhypertension AT safdarzeenat transitionfromselexipagtooraltreprostinilinapatientwithpulmonaryarterialhypertension |